Improved neutralisation of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech (BNT162b2) COVID-19 vaccine boosting with a third dose

  1. Kerri Basile
  2. Rebecca J Rockett
  3. Kenneth McPhie
  4. Michael Fennell
  5. Jessica Johnson-Mackinnon
  6. Jessica E Agius
  7. Winkie Fong
  8. Hossinur Rahman
  9. Danny Ko
  10. Linda Donavan
  11. Linda Hueston
  12. Connie Lam
  13. Alicia Arnott
  14. Sharon C-A Chen
  15. Susan Maddocks
  16. Matthew V O’Sullivan
  17. Dominic E Dwyer
  18. Vitali Sintchenko
  19. Jen Kok
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired 15 mutations in the receptor binding domain of the spike protein, raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three and six months post-two doses of Pfizer-BioNTech BNT162b2 has a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres are boosted. Despite this increase, neutralising antibody titres are reduced four-fold for Omicron compared to lineage A.2.2 SARS-CoV-2.

Related articles

Related articles are currently not available for this article.